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Background: Oral lichen planus (OLP) is seen frequently in patients with hepatitis C virus (HCV) infection. The aim
of this study was to evaluate the occurrence of oral candidiasis, other mucosal lesions, and xerostomia during
interferon (IFN) therapy for HCV infection.
Methods: Of 124 patients with HCV-infected liver diseases treated with IFN therapy in our hospital, 14 (mean age
56.00 ± 12.94 years) who attended to receive administration of IFN once a week were identified and examined for
Candida infection and other oral lesions and for the measurement of salivary flow. Serological assays also were
carried out.
Results: Cultures of Candida from the tongue surfaces were positive in 7 (50.0%) of the 14 patients with HCV
infection at least once during IFN therapy. C. albicans was the most common species isolated. The incidence of
Candida during treatment with IFN did not increase above that before treatment. Additional oral mucosal lesions
were observed in 50.0% (7/14) of patients: OLP in three (21.4%), angular cheilitis in three (21.4%) and recurrent
aphthous stomatitis in one (7.1%). OLP occurred in one patient before treatment with IFN, in one during treatment
and in one at the end of treatment. 85.7% of the oral lesions were treated with topical steroids. We compared the
characteristics of the 7 patients in whom Candida was detected at least once during IFN therapy (group 1) and the
7 patients in whom Candida was not detected during IFN therapy (group 2). The prevalence of oral mucosal lesions
(P=0.0075) and incidence of external use of steroids (P=0.0308) in group 1 were significantly higher than in group 2.
The average body weight of group 1 decreased significantly compared to group 2 (P=0.0088). Salivary flow
decreased in all subjects throughout the course of IFN treatment and returned at 6th months after the end of
treatment. In group 1, the level of albumin at the beginning of the 6th month of IFN administration was lower than
in group 2 (P=0.0550). According to multivariate analysis, one factor, the presence of oral mucosal lesions, was
associated with the detection of Candida. The adjusted odds ratio for the factor was 36.00 (95% confidence interval
2.68-1485.94).
Conclusion: We should pay more attention to oral candidiasis as well as other oral mucosal lesions, in patients
with weight loss during IFN treatment.* Correspondence: nagao@med.kurume-u.ac.jp
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Hepatitis C is a major global public health problem and
hepatitis C virus (HCV) infection is one of the main
causes of cirrhosis and hepatocellular carcinoma (HCC).
Interferon (IFN) therapy reduces the incidence of hepa-
tocarcinogenesis in patients with hepatitis C and improves
the long-term prognosis [1-4]. The standard therapy is a
combination of pegylated interferon (Peg-IFN) and riba-
virin (RBV). In addition, Peg-IFN, RBV, and telaprevir
triple therapy is a new strategy expected to eradicate
the HCV even in patients infected with difficult-to-treat
genotype 1 strains, although adverse effects, such as
anemia and rash, are frequent [5,6].
Extrahepatic manifestations of HCV infection are
numerous [7-10]. The most common diseases asso-
ciated with HCV are hematologic, dermatologic, renal,
and rheumatologic diseases.
Lichen planus (LP) is a chronic and mucocutaneous
disease that can affect the oral mucosa, skin, genital
mucosa, scalp and nails. A significant association be-
tween LP and chronic HCV infection has been reported
in Japan, Italy, and Spain [11-16]. Previously, we reported
that HCV was associated closely with extrahepatic mani-
festations such as oral LP (OLP) [12] and reported the
examination of hepatitis C patients for oral lesions before,
during and after IFN treatment [17,18]; OLP was seen in
11.7 (11/94)-16.7% (4/24). OLP can occur, become exacer-
bated and persist during IFN treatment for hepatitis C,
even when serum HCV RNA becomes negative. Our study
suggested that OLP pathogenesis in hepatitis C may be
attributed to host factors induced by HCV infection,
rather than direct pathological effects of the virus [17].
Candida generally causes no problems in healthy
people. Candida is commonly cultured from oral muco-
sal lesions. Overgrowth of Candida, however, can lead
to local discomfort, an altered taste sensation, dysphagia
from esophageal overgrowth resulting in poor nutrition,
slow recovery, and prolonged hospital stays [19]. Risk
factors associated with symptomatic candidiasis include:
local or systemic immunosuppression, haematological dis-
orders, broad-spectrum antibiotic use, inhaled or systemic
steroids, xerostomia, diabetes, wearing dentures, obtura-
tors and orthodontic appliances, and smoking [20-23].
Candida is has been reported to be found in 37.0% to
76.7% of OLP cases [24,25]. The treatment of OLP with
steroids is known to lead to secondary yeast infection,
which may complicate the treatment of OLP. C. albicans,
C. glabrata and C. tropicalis have been isolated from
OLP lesions treated with topical steroids [25].
Xerostomia is known as one of the adverse events
observed during IFN therapy [26,27]. Aghemo et al.
reported that dry mouth occurring during IFN therapy
results from a reversible inhibition of salivary gland func-
tion and that RBV causes salivary gland hypofunction [27].We also reported the salivary flow rate during IFN therapy
[18,28]. In a Japanese Phase III trial of Peg-IFN alfa-2a
and RBV involving 199 patients with chronic hepatitis C,
including 99 patients with IFN treatment-naive genotype
1 and 100 patients with patients whom had not had a
SVR after IFN therapy, 6.5% of all patients developed dry
mouth. On the other hand, in a Japanese Phase III trial
of Peg-IFN alfa-2b and RBV involving 332 chronic hepa-
titis C patients, including 269 patients for 48 weeks treat-
ment duration with genotype 1b and high virus load, and
63 patients for 24 weeks treatment duration with others,
15.6% of all patients developed dry mouth.
There have been few reports on oral Candida before,
during and after IFN treatment for chronic hepatitis C
patients. The aims of this study were to determine the
incidence of Candida as well as the development of
OLP, angular cheilitis, recurrent aphthous stomatitis,
and xerostomia, in the course of IFN treatment of
patients with chronic hepatitis C.
Materials and methods
Patients
A total of 124 consecutive HCV-infected patients for
whom IFN therapy was planned had checkups for oral
mucosal diseases, based on our hospital’s clinical path-
way in the Digestive Diseases Center at Kurume Univer-
sity Hospital Japan from July 30, 2008 to October 28,
2009. In this Digestive Diseases Center, physicians,
surgeons, radiologists and an oral surgeon examine each
patient in their own specialized area.
Seventeen of 124 patients agreed to the simultaneous
consultation of the hepatologist and oral surgeon in our
Digestive Diseases Center in order to receive administra-
tion of Peg-IFN and an oral examination once per week.
The other 107 patients did not consult a doctor every
week. Fourteen patients completed therapy. Three patients
discontinued IFN treatment because of null-response.
Systemic autoimmune disorders such as autoimmune
hepatitis, and Sjögren’s syndrome were considered as
exclusion criteria for IFN therapy.
The 14 patients, 3 men and 11 women, who completed
IFN therapy were examined. They ranged in age from 25
to 70 years, with an average age of 56.00 ± 12.94 years.
Eleven patients with HCV genotype 1 received adminis-
tration of Peg-IFN/RBV for 48-72 weeks. Two patients
with HCV genotype 2 received administration of
Peg-IFN/RBV for 24 weeks, and one patient with liver
cirrhosis (HCV genotype 2) received administration of
IFN beta for 24 weeks.
Methods
Examination of oral mucosal disease
We questioned the subjects about their frequency of
tooth-brushing. We used the headband fiber (50-100-10,
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luces for mucosal examination. Oral biopsy was per-
formed on some patients. The diagnosis of OLP was
made on the basis of clinical and/or histopathological
features. All patients were examined before IFN ther-
apy, at the beginning of the 2nd week of IFN administra-
tion, at the beginning of the 3rd month of IFN
administration, at the beginning of the 6th month of
IFN administration, at the end of IFN therapy, and at
6th months after the end of treatment. The patients
were weighed at each hospital visit. When a patient
complained of haphalgesia and a burning sensation
from oral musocal lesions, we prescribed external ster-
oids, such as 0.1% Dexamethasone (DexaltinW Nippon
Kayaku Co., Ltd, Tokyo, Japan), Triamcinolone aceto-
nide (AphthasealW Taisho Toyama Pharmaceutical Co.,
Ltd, Tokyo, Japan), and Beclometasone dipropionate
(SalcoatW Teijin Pharma Co., Ltd, Tokyo, Japan).
Salivary flow
Salivary flow was measured in all patients. We used a
simple and low-cost test for detection of xerostomia and
this required chewing on a piece of gauze for 2 min. A
salivary flow rate of below 2 g/2 min was judged as
decreased salivary secretion. All patients were examined
before IFN therapy, at the beginning of the 2nd week of
IFN administration, at the beginning of the 3rd month
of IFN administration, at the beginning of the 6th month
of IFN administration, at the end of IFN therapy, and
at 6th months after the end of treatment.
Candida isolation
We examined Candida species on the surface of the
tongue in 14 patients with chronic liver diseases before,
during, and after IFN therapy. The surface of the tongue
was rubbed ten times with cotton swabs and these were
placed on CHROMagar Candida slants. CHROMagar
Candida medium (CHROMagar, Paris, France) was pre-
pared according to the manufacturer’s instructions. The
swab was inoculated into CHROMagar Candida medium
by rotating the swab head on the surface of the medium.
The plates were incubated at 35oC for 48 h. Colony
morphology and colour description were assigned in a
standard manner by a single investigator.
When a patient diagnosed with candidiasis complained
of a burning sensation in the oral cavity, we adminis-
tered an antifungal agent, such as Miconazole (FloridW
Mochida Pharmaceutical Co., Ltd, Tokyo, Japan) and
Itraconazole (ItrizoleW Janssen Pharmaceutical K.K.,
Tokyo, Japan).
Serological assays
At each visit to our hospital for administration of IFN,
the patients were tested for platelets (PLT), white bloodcell (WBC), and hemoglobin (Hb), and for the following
liver function tests: serum alanine aminotransferase
(ALT), aspartate aminotransferase (AST), lactate de-
hydrogenase (LDH), total bilirubin (T.Bil) and albumin
(Alb). The presence of anti-SS-A and anti-SS-B anti-
bodies in all patients was tested by using an enzyme-
linked immunosorbent assay (ELISA). The normal levels
of anti-SS-A (SS-A/Ro(E)[S]; TFB, Ink, Japan) and anti-
SS-B (SS-B/La(E)[S]; TFB, Ink, Japan) are less than
10 U/mL, respectively.
Evaluation of liver diseases
HCV RNA was analyzed in serum by quantitative PCR
assay (COBAS AMPLICOR HCV MONITOR v 2.0 Test,
COBAS AmpliPrep/COBAS Taq-Man HCV Test, Roche
Molecular Systems, New Jersey, US) [29,30]. HCV geno-
type was determined by polymerase chain reaction assay,
using a mixture of primers for the subtype, as reported
previously [31]. Ultrasonographic examination was per-
formed on all patients in order to investigate the shape
of the liver and lesions occupying the liver. Computed
tomography and liver biopsy were performed on some
patients. We used other possible predictors of progres-
sion of liver cirrhosis, including serum Alb, T.Bil, pro-
thrombin time, and PLT.
Ethical considerations
This investigation was undertaken with the understand-
ing and consent of each participating subject and has
been conducted in full accordance with ethical princi-
ples of the World Medical Association Declaration of
Helsinki. The Ethical Committee of Kurume University
concluded that this study was not included in an ethic
guideline because this study is a medical practice aimed
for diagnosis and treatment.
Statistical analysis
All data are expressed as mean ± standard error. Differ-
ences between the two groups were analyzed using the
Mann-Whitney U test, Wilcoxon’s test, and the Fisher’s
exact test. Differences were judged significant for p <0.05
(two-tailed). Adjusted odds ratios were calculated using
logistic regression analysis. All statistical analyses were
conducted using JMP Version 6 (SAS Institute, Cary,
NC, USA). The level of statistical significance was
defined as 0.05.
Results
Incidence of positive Candida cultures and development
of oral mucosal lesions
Cultures of Candida from the tongue surfaces were
positive in seven (50.0%) of the 14 patients with HCV
infection at least once during IFN therapy. Table 1 shows
the association of the incidence of positive Candida
Table 1 Characteristics of the subjects
















3 M after IFN
1 70 F CH-C 1b High Peg-IFN/RBV − − −
2 52 M CH-C 1b High Peg-IFN/RBV + + +
C. albicans 3 C. albicans 1 C. albicans
OLP OLP OLP
3 33 F CH-C 1b High Peg-IFN/RBV + − −
C. albicans 2
4 53 F LC-C ND
(serogroup 2)
Low IFN beta − − −
5 70 F CH-C 2a High Peg-IFN/RBV + − +
C. albicans 1 C. albicans
C. parapsilosis
6 60 F CH-C 2a High Peg-IFN/RBV − − −
7 57 F CH-C 1b High Peg-IFN/RBV + − +




8 58 F CH-C 1b High Peg-IFN/RBV − − −
9 25 F CH-C 1b High Peg-IFN/RBV − − −
10 54 F CH-C 1b High Peg-IFN/RBV − − −
11 61 F CH-C 1b High Peg-IFN/RBV + − +
C. albicans 1 C. albicans
angular
cheilitis
12 69 F CH-C 1b High Peg-IFN/RBV + − +
C. albicans 1 C. albicans
13 60 M CH-C 1b High Peg-IFN/RBV − − −
14 62 M CH-C 1b Low Peg-IFN/RBV − − −
OLP
Incidence of Candida
or mucosal lesions (%)
42.86% 7.14% 35.71%
Total colonies (n) 10 1
C. albicans (the number of patients) 6 1 5
C. parapsilosis (the number of patients) 0 0 1
C. lusitaniae (the number of patients) 0 0 0
C. tropicalis (the number of patients) 0 0 0



























− − − − − group 2
+ + + + + group 1
1 C. albicans 1 C. albicans 1 C. albicans 2
C. tropicalis 1
OLP OLP OLP
− − − − − group 2
− − − − − group 2
+ + − + + group 1
1 C. albicans 2 C. albicans 2
1
angular cheilitis
− − − − − group 2
+ + + + + group 1





+ − − + − group 1
C. albicans 1
− − − − − group 2
− − − − + group 2
OLP OLP
+ − − + + group 1
1 C. albicans 1
+ + + + + group 1
1 C. albicans 1 C. albicans 1 C. albicans 1
angular cheilitis
− − − − − group 2
− + − + + group 1
C. lusitaniae 1
OLP OLP OLP
42.86% 35.71% 21.43% 50.00% 50.00%





HCV, hepatitis C virus; CH-C, chronic hepatitis C; LC-C, liver cirrhosis type C; OLP, oral lichen planus; C., Candida; IFN, interferon; Peg-IFN, pegylated interferon; RBV,
ribavirin; M, male; F, female; ND, not detected; −, negative; +, positive.
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Candida cultures was 42.86% (6 cases, C. albicans) be-
fore IFN therapy, 7.14% (1 case, C. albicans) at the be-
ginning of the 2nd week of IFN administration, 35.71%
(4 cases, C. albicans; 1 case, C. albicans and C. parapsilosis)
at the beginning of the 3rd month of IFN administration,
42.86% (6 cases, C. albicans) at the beginning of the 6th
month of IFN administration, 35.71% (4 cases, C. albicans;
1 case, C. lusitaniae) at the end of IFN therapy and
21.43% (2 cases, C. albicans; 1 case, C. albicans and C.
tropicalis) at 6th months after the end of treatment. C.
albicans was the most common species isolated from
tongue surfaces. The incidence of Candida during
treatment with IFN did not increase above that before
treatment.
Oral mucosal lesions were observed in 50.00%
(7/14) of patients: three with OLP (21.43%, 2 men and
1 woman), three with angular cheilitis (21.43%, 3 women)
and one with recurrent aphthous stomatitis (7.14%,
1 woman). OLP occurred in one patient before treatment
with IFN, in one during treatment and in one at the end
of treatment (Table 1). Patient no. 2 (a 52 year old male)
had erosive OLP before IFN therapy; his lesions became
exacerbated during IFN therapy but he was able to
complete the therapy because of improvement with ster-
oid application.
We administered antifungal agents to two patients
(nos. 2 and 5 in Table 1) with candidiasis who com-
plained of burning pain and prescribed external steroids
for six patients (nos. 2, 5, 7, 10, 11, and 12 in Table 1)
with oral mucosal lesions.Comparison between Candida positive and negative
groups
We compared the characteristics of the 7 patients
(group 1) in whom Candida was detected at least once
during IFN therapy and the 7 patients (group 2) in
whom Candida was not detected during treatment
(Table 2). The prevalence of oral mucosal lesions and
incidence of external use of steroids were 85.71% (6/7)
and 71.43% (5/7), respectively, in group 1 and 14.29%
(1/7) and 14.29% (1/7), respectively, in group 2. The
prevalence of oral mucosal lesions (P=0.0075) and inci-
dence of external use of steroids (P=0.0308) was signifi-
cantly higher in group 1 than group 2. The diagnosis of
oral mucosal disease in group 1 included: OLP (n=2),
angular cheilitis (n=3), and recurrent aphthous stoma-
titis (n=1). That in group 2 was OLP (n=1).
Body weight decreased significantly in group 1 during
IFN therapy, compared to group 2 (P=0.0088). Number
of neutrophils, PLT, Alb, and Hb decreased in all subjects
throughout the course of IFN treatment. In group 1, the
level of Alb at the beginning of the 6th month of IFNadministration was lower than in group 2 (P=0.0550,
Table 2). The number of times teeth were brushed after
every meal was lower in group 1 than group 2.
Salivary flow
Salivary flow decreased in all subjects throughout the
course of IFN treatment and returned at 6th months after
the end of treatment (Table 2). Salivary flow was 6.10 ±
1.81 g/2 min before IFN therapy, 5.71 ± 2.60 g/2 min
at the beginning of the 2nd week of IFN administration,
5.23 ± 2.14 g/2 min at the beginning of the 3rd month
of IFN administration, 5.42 ± 1.97 g/2 min at the begin-
ning of the 6th month of IFN administration, 5.31 ± 2.06 g/
2 min at the end of IFN therapy and 6.02 ± 1.81 g/2 min at
6th months after the end of treatment. There was no sig-
nificant difference in the salivary flow between group 1
and group 2.
Multivariate analysis
According to multivariate analysis, one factor, the
presence of oral mucosal lesions, was associated with
the detection of Candida. The adjusted odds ratio for the
factor was 36.00 (95% confidence interval 2.68-1485.94).Discussion
Oral Candida albicans is known to have been isolated
from patients with OLP [24,25]. Some Candida albicans
isolates with special virulence attributes might be co-
factors which contribute to the development of OLP,
especially erosive OLP [32]. The erosive OLP can cause
spontaneous pain during eating and tooth-brushing.
There have been few reports of the detection of oral
Candida before, during and after IFN treatment for
chronic hepatitis C. In this study, Candida was detected
in 50.0% of patients with HCV-related chronic liver dis-
ease and who received IFN treatment. The most signifi-
cant factor associated with Candida was the presence of
oral mucosal lesions associated with IFN therapy. 85.71%
(6/7) of the oral lesions were treated with topical steroids.
We found no correlation between HCV genotype, levels
of HCV RNA, IFN type, dose or administration schedule,
or effect of IFN therapy with Candida detection.
Poor oral health has been reported in HCV-infected
patients [33-36]. Coates et al. reported that the experi-
ence of dental caries was significantly worse in HCV-
infected subjects than in patients in general [33]. Griffin
et al. found that patients with rheumatoid arthritis,
diabetes or a liver condition were twice as likely to have
an urgent need for dental treatment as patients who did
not have these diseases and documented a high burden
of unmet dental care needs among patients with chronic
diseases [36]. The authors showed that HCV was the
strongest predictor of patients reporting poor oral health.
Table 2 Comparison between Candida positive and negative groups
Total Goup 1 Group 2 P value
Subjects (n) 14 7 7
Sex (M/F) 3/11 2/5 1/6 NS
Age (mean ± SD) 56.00 ± 12.94 61.30 ± 6.47 50.71 ± 16.00 NS
HCV genotype 1b 11 (78.57%) 6 (85.71%) 5 (71.43%) NS
2a 2 (14.29%) 1 (14.29%) 1 (14.29%) NS
ND (serotype 2) 1 (7.14%) 0 (0%) 1 (14.29%) NS
HCV RNA level High 12 (85.71%) 6 (85.71%) 6 (85.71%) NS
Low 2 (14.29%) 1 (14.29%) 1 (14.29%) NS
Weight loss during IFN therapy 5.69 ± 4.57 8.71 ± 2.81 2.66 ± 4.00 0.0088
Neutrophil count (μ/L) Before IFN 2546.11 ± 793.47 2481.34 ± 599.67 2610.89 ± 997.36 NS
2 weeks after IFN 1229.11 ± 590.25 1260.51 ± 473.58 1197.70 ± 726.82 NS
3 months after IFN 1343.05 ± 584.48 1636.51 ± 670.69 1049.59 ± 298.98 NS
6 months after IFN 1319.11 ± 301.15 1442.69 ± 194.15 1195.53 ± 350.95 NS
End of treatment 1360.21 ± 547.74 1420.54 ± 401.41 1299.87 ± 693.13 NS
6 months after treatment 2349.21 ± 695.36 2578.63 ± 716.47 2119.80 ± 641.48 NS
PLT (x10-4/μL) Before IFN 17.58 ± 7.06 17.54 ± 3.32 17.61 ± 9.84 NS
2 weeks after IFN 14.04 ± 7.28 14.37 ±4.70 13.71 ± 9.61 NS
3 months after IFN 13.69 ± 6.08 14.27 ± 5.36 13.11 ± 7.12 NS
6 months after IFN 13.20 ± 5.31 14.21 ± 4.72 12.19 ± 6.03 NS
End of treatment 14.45 ± 5.05 14.50 ± 4.59 14.40 ± 5.84 NS
6 months after treatment 16.86 ± 6.03 18.14 ± 4.29 15.59 ± 7.52 NS
Hb (g/dL) Before IFN 13.97 ±1.08 13.91 ±1.26 14.03 ± 0.97 NS
2 weeks after IFN 13.04 ±1.06 13.33± 1.34 12.76 ± 0.67 NS
3 months after IFN 10.94 ±1.55 10.40 ±1.57 11.47 ±1.45 NS
6 months after IFN 10.61 ±1.73 9.81 ± 1.45 11.41 ± 1.70 NS
End of treatment 10.99 ±1.74 10.23 ± 1.89 11.74 ± 1.27 NS
6 months after treatment 13.29 ±1.48 12.99 ± 2.05 13.59 ± 0.58 NS
Alb (g/dL) Before IFN 4.18 ± 0.35 4.10 ± 0.34 4.26 ± 0.36 NS
2 weeks after IFN 3.76 ± 0.48 3.75 ± 0.38 3.76 ± 0.59 NS
3 months after IFN 3.84 ± 0.37 3.76 ± 0.45 3.92 ± 0.28 NS
6 months after IFN 3.88 ± 0.33 3.74 ± 0.42 4.02 ± 0.12 0.0550
End of treatment 3.90 ± 0.38 3.77 ± 0.35 4.03 ± 0.39 NS
6 months after treatment 4.27 ± 0.35 4.23 ± 0.34 4.30 ± 0.39 NS
Salivary flow (g/2 min) Before IFN 6.10 ± 1.81 5.86 ± 1.90 6.38 ± 1.81 NS
2 weeks after IFN 5.71 ± 2.60 5.88 ± 2.33 5.55 ± 3.03 NS
3 months after IFN 5.23 ± 2.14 4.92 ± 2.34 5.53 ± 2.06 NS
6 months after IFN 5.42 ± 1.97 5.32 ± 2.14 5.51 ± 1.94 NS
End of treatment 5.31 ± 2.06 5.33 ± 1.58 5.30 ± 2.58 NS
6 months end of IFN 6.02 ± 1.81 6.03 ± 1.38 6.00 ± 2.28 NS
Diabetes mellitus positive, n (%) 2 (14.29%) 1 (14.29%) 1 (14.29%) NS
Oral mucosal lesions positive, n (%) 7 (50.00%) 6 (85.71%) 1 (14.29%) 0.0075
Steroid for external use positive, n (%) 6 (42.86%) 5 (71.43%) 1 (14.29%) 0.0308
Tooth-brushing after every meal yes, n (%) 8 (57.14%) 3 (42.86%) 5 (71.43%) NS
Denture wearer yes, n (%) 0 (0%) 0 (0%) 0 (0%) NS
Administration of antifungal agent yes, n (%) 2 (14.29%) 2 (28.57%) 0 (0%) NS
Effect of IFN therapy SVR , n (%) 11 (78.57%) 6 (85.71%) 5 (71.43%) NS
HCV, hepatitis C virus; IFN, interferon; M, male; F, female; ND, not detected; NS, not significant; PLT, platelets; Hb, hemoglobin; Alb, albumin.
Nagao et al. BMC Gastroenterology 2012, 12:155 Page 7 of 9
http://www.biomedcentral.com/1471-230X/12/155
Nagao et al. BMC Gastroenterology 2012, 12:155 Page 8 of 9
http://www.biomedcentral.com/1471-230X/12/155In our study, there was a high rate of detection of can-
dida species in patients who did not brush their teeth
after every meal, compared to those who did so. Oral
hygiene should be encouraged in patients during IFN
treatment.
In our previous study, dental problems delayed the ini-
tiation of IFN therapy for up to 105 days [28]. HCV-
infected patients treated with IFN should be managed by
intensive oral care because of lower resistance to infec-
tion during the therapy. With regard to the painful OLP,
it is just conceivable that an oral cavity with HCV infec-
tion is likely to become less healthy than one without
HCV infection. REFRECARE-HW (EN Otsuka Pharma-
ceutical Co. Ltd. Iwate, Japan) is an oral care gel con-
taining hinokitiol, which can remove stains on the teeth
and general oral debris, and is effective in the prevention
of breath odor and gum diseases. Hinokitiol has significant
antimicrobial efficacy against Staphylococcus aureus,
Propionibacterium acnes, coronavirus, Trichophyton,
and Candida albicans [37]. We reported that this oral
care gel improved the subjective symptoms of all
patients with OLP [38].
IFN therapy for HCV infection is associated with
various side effects, including a greater level of fatigue,
loss of appetite, weight loss, sleep problems, and depres-
sion. In the present study, weight loss during IFN therapy
lead to oral candidiasis. Weight loss is considered to be
the important risk factor for oral candidiasis. Back-Brito
GN et al. demonstrated that eating disorders can lead to
an increased oral Candida carriage [39].
Our study showed that hypoalbuminemia during IFN
therapy might lead to oral candidiasis. We reported previ-
ously a strong association between hypoalbuminemia and
mortality in a hyperendemic area (X town) of HCV infec-
tion in Japan [40] and that hypoalbuminemia was an in-
dependent risk factor for the development of OLP [41].
Several studies have shown an association between
HCV and Sjögren's symdrome (SS) [42,43]. In this study,
we demonstrated that the salivary flow of all patients with
HCV infection decreased during IFN treatment and
increased again after treatment. Various investigators have
reported a high prevalence of oral Candida species in
patients with SS, compared to healthy controls [44-46].
Japanese HCV-infected patients tend to be older than
those in other countries and their older age favors the
onset of HCC. In addition, oral candidiasis is underdiag-
nosed among the elderly [19]. Therefore, we require
careful attention to the oral cavities of patients who
receive IFN therapy.Conclusion
In conclusion, our data show that IFN therapy led to the
development of oral mucosal lesions, leading to oralcandidiasis, and inhibited salivary secretion. We should
pay more attention to oral candidiasis as well as additional
oral mucosal lesions, in patients with weight loss during
IFN treatment. Patients with HCV infection emphasize
the paramount importance of oral management.
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